Onco Wiki / drapeau rouge

Syndrome de différenciation APL (anciennement PR-syndrôme): fièvre, dyspnée, prise de poids ≥5 kg, p...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Origine du drapeau rouge

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "differentiation_syndrome_active",
      "value": true
    },
    {
      "finding": "rising_wbc_on_atra",
      "value": true
    },
    {
      "comparator": ">",
      "finding": "wbc_rise_during_induction",
      "threshold": 10
    },
    {
      "all_of": [
        {
          "finding": "fever_unexplained",
          "value": true
        },
        {
          "finding": "new_dyspnea",
          "value": true
        },
        {
          "comparator": ">=",
          "finding": "weight_gain_kg",
          "threshold": 5
        }
      ]
    }
  ],
  "type": "symptom_composite"
}

Notes

Direction "investigate" — surfaces a monitoring annotation rather than shifting indication. Triggers immediate dexamethasone 10 mg IV BID, consideration of temporary ATRA/ATO hold (per severity), aggressive diuresis, ICU monitoring. Prophylactic steroids (prednisone 0.5 mg/kg or dexamethasone 2.5 mg/m² BID) are recommended for high-risk (WBC >10) and any patient with rising WBC during induction. DS occurs in ~5-25% and is a leading cause of induction mortality if not promptly recognized. STUB — requires clinical co-lead signoff.

Utilisé par

Algorithmes

• ALGO-APL-1L - ALGO-APL-1L
• ALGO-APL-2L - ALGO-APL-2L

Indication

• IND-APL-RELAPSED-GEMTUZUMAB - IND-APL-RELAPSED-GEMTUZUMAB